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Abstract 
Despite good cover with 7-valent vaccina-
tion, invasive pneumococcal infections may
still be misdiagnosed and may lead to life-
threatening situations or death in young chil-
dren. New serotypes are emerging and, there-
fore, clinicians must keep a high level of suspi-
cion in young children regardless of their vac-
cination status. We report three cases of inva-
sive pneumococcal infection due to new
serotypes not covered by the 7-valent conjugat-
ed vaccine, two of which led children to death.
Introduction
Considerable progress has been achieved in
both prevention and management of invasive
pneumococcal infections (IPI). Yet high fatali-
ty rates ranging from 2.6% to 6% have been
reported in industrialized countries.1 In
Switzerland, Gessler et al. have reported an
age specific incidence of IPI of: 33.1% in chil-
dren below 1st year of age, 28.8% under 2 years,
13.4% between 2 and 4 years and 3.1% between
5 and 6 years, highlighting hence the higher
vulnerability in toddlers.2 In 1983, the first vac-
cine against 23 serotypes of Streptococcus
Pneumoniae was unfortunately not effective in
children under the age of 2. The implementa-
tion of a 7-valent conjugated vaccine (7-VCV)
in 2000 reduced IPI by 87% in children below 1
year, 58% under 2 and 62% under 5.3 However,
in 2010, the Mortality and Morbidity Weekly
Report despite confirming the decrease in
resistance and carriage of pneumococcal
serotypes contained in the 7-VCV, noted a
sharp rise in other serotypes causing new
invasive pneumococcal diseases.4 That is why
clinicians must keep, regardless of vaccination
status in children with fever, a high level of
suspicion of IPI. We report three cases of
severe IPI in vaccinated children.
Case Reports
Case #1
An 11-months-old girl with unremarkable
medical history, who had received two doses of
7-VCV, presented with chief complaint of 10
min partial seizure involving left hemi-face.
Three days prior to presentation she had devel-
oped high fever (40°C) that was associated
with diarrhea and vomiting. Seizure activity
had ceased upon arrival on emergency ward
and was soon after followed by another gener-
alized seizure lasting 45 min and requiring 5
mg intra-rectal diazepam and 0.2 mg intra-
venous clonazepam to resolve. On admission, a
post ictal left facial paralysis was noted, which
spontaneously resolved 3 h later. Clinical
examination revealed bilateral acute otitis
media. Initial work-up showed mildly raised C-
reactive protein (CRP 54 mg/L), white blood
cell (WBC) count 25.3 G/L with 13.5% imma-
ture granulocytes. As the child was recovering
normal clinical status, the diagnosis retained
was an atypical febrile seizure, and the child
was admitted for observation for 24 h. During
the night she presented tonico-clonic seizures
associated with loss of consciousness, bilater-
al mydriasis and right-sided hemi syndrome
that was managed with two injections of ben-
zodiazepine. The child’s neurological status
remained seriously impaired with Glasgow
Coma Scale (GCS) of 9, and left-sided hemi
paresis. The second laboratory work-up
showed a CRP of 260 mg/L, WBC 12.0G/L and
42% immature forms. Cerebral computed
tomography (CT)-scan showed severe right-
sided brain edema with significant deviation
of midline structures to the left. A dose of 100
mg/kg of Ceftriaxone was administered and
the child transferred to Pediatric Intensive
Care Unit (PICU) where her condition wors-
ened with hemodynamic instability and GCS of
4, needing mechanical ventilatory support and
vasopressive therapy. Decompression cran-
iotomy showed mildly raised intracranial pres-
sure (18 mm Hg), signs of purulent meningitis
as well as multiple brain abscesses.
Microbiologic cultures were positive for
Streptococcus pneumonia serotype 1 [blood,
urines, cerebrospinal fluid (CSF) and
nasopharyngeal secretions]. Despite very
active management, she developed diabetes
insipidus; the brain magnetic resonance imag-
ing (MRI) performed on day 5 showed wide-
spread bilateral cytotoxic edema and necrosis
and electroencephalogram (EEG) major corti-
cal depression. The child died on day 6. 
Case #2
A 2-year-old child was admitted to the emer-
gency ward with a three days history of fever
(40.7°C) associated with lethargy, headache
and five episodes of vomiting. His past medical
history was unremarkable; he had received 3
doses of 7-VCV. Physical examination revealed
tachycardia (124/’), tachypnea (40/’), pallor,
mild signs of dehydration and right acute otitis
media. Although he was drowsy, he responded
normally to verbal stimuli. Neurological exam-
ination revealed minimal nuchal stiffness, a
dubious Kernig and Brudzinski with no focal
neurological signs. A fluid bolus with normal
saline was administered along with 100 mg/kg
ceftriaxone. The clinical response was rapid,
his general condition improved and he was
able to take few steps. He was admitted to the
ward for observation.
Suddenly, his condition worsened with the
occurrence of generalized tonico-clonic
seizures with left lateralization that stopped
after intravenous administration of 0.5 mg/kg
diazepam. Physical examination at this point
revealed areactive bilateral mydriasis and
altered consciousness with GCS of 8. The child
also developed rapidly Cushing’s triad (systolic
blood pressure 160 mmHg, bradycardia 80/’
and irregular respiratory pattern). He was rap-
idly intubated and transferred to the PICU for
subsequent management. Cerebral CT-scan
showed extensive cerebral oedema with lateral
ventricles collapse, and right-sided acute mas-
toiditis. Despite maximal neurological support,
hypertonic fluid administration (mannitol and
3% NaCl) and corticosteroid treatment, his
state worsened: bilateral non-reactive mydria-
sis persisted along with a loss of brainstem
reflexes. Intracranial hypertension was com-
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plicated by diabetes insipidus requiring
desmopressin therapy. Hemodynamic instabil-
ity developed, requiring a vasoactive treatment
with norepinephrine and dopamine. The labo-
ratory work-up showed raised CRP 305
mg/lLand WBC of 90 G/L. Microbiologic cul-
tures were positive for Streptococcus
Pneumoniae serotype 7. Viral tests in CSF
(herpes, varicella, Epstein-Barr virus,
Parvovirus, cytomegalovirus, adenovirus)
remained negative. A second cerebral CT-scan
performed six hours after admission to PICU to
evaluate the indication for decompression
craniotomy showed an extensive cerebral
edema with absent cerebral perfusion. EEG
was non-reactive and the cerebral MRI con-
firmed the diffuse cerebral edema without
cerebral perfusion. The child died on day 2.
The autopsy confirmed pneumococcal menin-
goencephalitis. 
Case #3
A one-year old girl, with unremarkable past
history and two doses 7-VCV developed high
fever (up to 39.5°C). On the same night, the
child’s conditions deteriorated, and she was
admitted on the following morning to Pediatric
Emergency Room with tachycardia (210/’),
hypotension (70/50 mmHg), mottled skin with
cold extremities, tachypnea (60/’). Upon clini-
cal examination, a purpuric rash and neck
stiffness were noted. Meningococcal septic
shock was suspected and fluid resuscitation
immediately started, along with IV antibiotics
and corticosteroid therapy (ceftriaxone 100
mg/kg, hydrocortisone 2 mg/kg). Laboratory
investigations revealed metabolic acidosis (pH
7.13, bicarbonates 13 mmol/L and BE 12.5
mmol/L), hypoglycemia (1.4 mmol/L), raised
CRP 386 mg/L, procalcitonin 122 mcg/L. hyper-
leukocytosis 15 G/L with 20% immature bands)
and stigmata of intravascular disseminated
coagulation (thrombocytes 75 G/L, TP 19, PTT
121, fibrinogen 0.7 g/L).
As hemodynamic instability persisted,
vasoactive amines were started and the child
transferred to PICU where she required subse-
quent fluid resuscitation, fresh frozen plasma
to correct the coagulation parameters along
with the introduction of noradrenalin to stabi-
lize blood pressure. As she presented only mild
respiratory distress, non invasive ventilation
with bilevel positive airway pressure (8
mmHg) was initiated. Lumbar puncture
revealed hyperproteinemia and hypoglyco-
rachia but microbiology was negative. Blood
cultures, however, turned positive for
Streptococcus Pneumoniae (Serotypes 15B and
15C). Her status rapidly improved allowing
hemodynamic support to be withdrawn after 48
h. Corticosteroids were stopped after 5 days
and antibiotics after 2 weeks. The child was
discharged from hospital at the end of antibiot-
ic therapy.
One month later, she presented a second
episode of septic shock, identical to the first
that was managed with IV fluids and corticos-
teroids in the Pediatric Emergency Ward,
before transfer to PICU. Blood cultures showed
again Streptococcus Pneumoniae (serotype
15B and 15C) sensitive to ceftriaxone. Her
clinical course was identical to the first: she
received IV antibiotics, fluid resuscitation,
hemodynamic and ventilator support but no
intubation. Further investigations showed
asplenia and multiple osteomyelitis foci (right
humerus, right tibia and left radius).
Ceftriaxone was consequently pursued for 4
weeks, followed by oral amoxicillin (80
mg/kg/j) during a week. A prophylactic antibi-
otic regimen with oral penicillin was then pre-
scribed to prevent recurrence of severe septic
episodes.
Discussion
These three situations illustrate that IPI
occur frequently despite the presumed protec-
tion conferred by the 7-VCV. New serotypes are
emerging, equally virulent, and cause invasive
infections which may lead to death or life-
threatening situations. 
Most studies observe a decline in the inci-
dence of IPI after the introduction of the 7-VCV.
In the UK, the number of cases of IPI in chil-
dren under the age of five decreased by 41%
after vaccine introduction.5 In the United
States, pneumococcal meningitis incidence
decreased by 64% among children younger
than 2 years.6 Studies conducted in other
European counties and in Australia have also
concluded to overall reduction of IPI.7,8
However, as vaccination successfully diminish-
es colonization of vaccinated serotypes, it also
leaves a niche which is colonized by other
pneumococcal serotypes, eventually leading to
replacement diseases.9 This phenomenon has
been described in many countries after the
introduction of 7-VCV. In the United-States, for
instance, disease rates of non-vaccinated
serotypes increased by 60.5% and pneumococ-
cal meningitis caused by non-vaccinated
serotypes among children under two years
increased by 275%.6
Both serotypes 1 and 7, which were isolated
from our cases, significantly increased after
the introduction of the 7-VCV.7 In Scotland the
7F serotype was reported to be the most com-
mon serotype of IPI in 2009. Before vaccination
it had not been isolated from any IPI.5
However, serotype 1 increased in the UK
before vaccine implementation, which illus-
trates the fact that other factors apart from
vaccine pressure play a role in pneumococcal
epidemiology.5
Serotypes 1 and 7 are included in both vac-
cinations which were developed after the 7-
VCV (Prevenar 13® (Pfizer AG, Zürich,
Switzerland) and Synflorix® (Glaxo-
SmithKline SA, Belgium)].). These new vac-
cines may therefore have prevented invasive
pneumococcal infection in our 2 patients.
Indeed, the 13-valent pneumococcal vaccine
could have theoretically covered 50% of IPI in
the United States in 2004-2005 6, 60% of pneu-
mococcal meningitis in France in 2007-200810
and 73% of IPI in 2009 in Switzerland.11
One of these vaccines, Prevenar 13® (Pfizer
AG), is recommended in Switzerland only
since January 2011. The question remaining
is: will the introduction of these new vaccines
bring up other serotypes not yet known?
Continuous monitoring of the serotypes
involved in IPI is mandatory to adapt pneumo-
coccal vaccines consequently. 
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